This study is testing ivonescimab combined with chemotherapy against pembrolizumab combined with chemotherapy for people with metastatic (cancer that has spread) non-small cell lung cancer (NSCLC). Researchers want to see if ivonescimab can help people live longer and prevent their cancer from growing or spreading for a longer time. To join, you must be at least 18 years old, have metastatic NSCLC, and a good general health status (ECOG performance status of 0 or 1). Your doctor will also check your PD-L1 expression levels. The study aims to enroll about 1600 participants.

Study design

This is a Phase 3, randomized, double-blind study, meaning participants are assigned to a treatment group by chance and neither you nor your doctor will know which treatment you are receiving. It plans to enroll about 1600 participants.

What's involved

You will receive either ivonescimab or pembrolizumab, both given as an intravenous (IV) injection, along with chemotherapy. The trial record does not specify the number of visits or specific procedures.

Compensation

Not stated in the trial record.

Follow-up

Researchers will follow participants for overall survival for approximately 4 years and for progression-free survival for approximately 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.